Physician profile
Jujhar Singh
NPI 1821527375
$2,202.39
in general payments reported to CMS, 2019-2025
23 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $392 · 2024: $710 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $559.26 | 2023-2025 | Repatha, Repatha, Otezla |
| Abbott Laboratories | $239.04 | 2023-2024 | Proclaim, Freestyle Libre 3, Eterna |
| Inspire Medical Systems, INC. | $195.28 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $193.67 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $166.36 | 2024-2025 | |
| Corcept Therapeutics | $112.66 | 2024-2025 | Korlym |
| Lundbeck LLC | $107.03 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $92.79 | 2024-2025 | |
| Lilly USA, LLC | $72.54 | 2024-2025 | Mounjaro, Trulicity, Zepbound |
| Exact Sciences Corporation | $72.30 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $59.73 | 2023-2024 | Ubrelvy |
| Novo Nordisk INC | $56.48 | 2023 | Rybelsus, Ozempic |
| Pfizer INC. | $39.11 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.54 | 2024-2025 | Jardiance, Synjardy |
| Sumitomo Pharma America, INC. | $29.08 | 2025 | Gemtesa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $28.52 | 2025 | Rexulti |
| Boston Scientific Corporation | $25.46 | 2025 | Wavewriter Alpha Prime 16 |
| Dexcom, INC. | $23.86 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $22.92 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Biotronik Nro, INC. | $20.66 | 2023 | Biotronik |
| Eisai INC. | $17.21 | 2024 | |
| Neurocrine Biosciences, INC. | $15.54 | 2024 | |
| Abiomed | $14.35 | 2023 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jujhar Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.